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Abstract
Background: Iron-deficiency is the most common nutritional deficiency globally. Due to the high iron requirements
for pregnancy, it is highly prevalent and severe in pregnant women. There is strong evidence that maternal
iron deficiency anaemia increases the risk of adverse perinatal outcomes. However, most of the evidence is
from observational epidemiological studies except for a very few randomised controlled trials. IFA supplements have
also been found to reduce the preterm delivery rate and neonatal mortality attributable to prematurity and birth
asphyxia. These results combined indicate that IFA supplements in populations of iron-deficient pregnant women
could lead to a decrease in the number of neonatal deaths mediated by reduced rates of preterm delivery. In this
paper, we describe the protocol of a community-based cluster randomised controlled trial that aims to evaluate the
impact of maternal antenatal IFA supplements on perinatal outcomes.
Methods/design: The effect of the early use of iron-folic acid supplements on neonatal mortality will be examined
using a community based, cluster randomised controlled trial in five districts with 30,000 live births. In intervention
clusters trained BRAC village volunteers will identify pregnant women & provide iron-folic acid supplements.
Groundwater iron levels will be measured in all study households using a validated test kit. The analysis will follow the
intention to treat principle. We will compare neonatal mortality rates & their 95% confidence intervals adjusted for
clustering between treatment groups in each groundwater iron-level group. Cox proportional hazards mixed models
will be used for mortality outcomes & will include groundwater iron level as an interaction term in the mortality model.
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Discussion: This paper aims to describe the study protocol of a community based randomised controlled trial
evaluating the impact of the use of iron-folic acid supplements early in pregnancy on the risk of neonatal mortality.
This study is critical because it will determine if antenatal IFA supplements commenced in the first trimester of
pregnancy, rather than later, will significantly reduce neonatal deaths in the first month of life, and if this approach is
cost-effective.
Trial registration: This trial has been registered with the Australian New Zealand Clinical Trials Registry (ANZCTR) on
31 May 2012. The registration ID is ACTRN12612000588897.
Background
Globally, 2.6 million children died in the neonatal
period, the first 28 days of life in 2016 [1]. Over the last
two decades, there has been a substantial global reduc-
tion in under-5 child mortality rates. Compared to that,
the reductions in neonatal deaths have been slower.
Neonatal deaths accounted for 46% of all under-five
deaths in 2016 compared with 37·4% in 1990 [1, 2].
Effective interventions directed specifically at preventing
neonatal deaths are required to improve overall child
survival.
A systematic review in 2005 found that up to 70% of
neonatal deaths, worldwide, could be averted by imple-
menting sixteen evidence-based interventions at near uni-
versal coverage (99%) that incorporated preconception,
antenatal, intrapartum and postnatal interventions [3].
However, this review did not include antenatal iron and
folic acid (IFA) supplementation for pregnant women. At
that time no trials had reported the effects of IFA on
neonatal mortality, although these supplements were
known to benefit both maternal and infant health [3].
Iron-deficiency is the most common nutritional
deficiency globally. Due to the high iron requirements
for pregnancy, it is highly prevalent and severe in
pregnant women [4]. In Bangladesh, 42% of all women
of reproductive age and nearly 50% of pregnant women
had anaemia in 2011 [5]. However, the prevalence of
iron deficiency was lower. The first national micronutri-
ents status survey, published in early 2013, reported that
iron deficiency among non-pregnant non-lactating
women was 7.1%. The ferritin level was significantly
higher in areas where groundwater iron concentration
was high. The survey findings also suggest a positive as-
sociation between natural iron content in groundwater
and iron status of women [6].
There is strong evidence that maternal iron deficiency
anaemia increases the risk of adverse perinatal out-
comes. However, most of the evidence is from observa-
tional epidemiological studies except for a very few
randomised controlled trials. A community-based cluster
randomised trial from China reported a 54% reduction
of early neonatal mortality in newborns of women who
received IFA supplements compared to those receiving
folic acid alone (HR 0.46, 95%CI: 0.21–0.98) [7]. Second-
ary analyses of this trial found a 71% reduction in neo-
natal mortality in women who started IFA supplements
in the first trimester of pregnancy (HR 0.29, 95%CI:
0.09–0.88) [8]. A meta-analysis of prospective observa-
tional studies, reported reductions in perinatal mortality
(stillbirth and early neonatal mortality) with each 1 g/dl
increase in the population mean haemoglobin (RR 0.72,
95%CI: 0.65–0.81) [9]. A pooled analysis of data from
Indonesian Demographic and Health Surveys, which in-
cluded 40,576 singleton live-born infants, found mothers
using any IFA supplements during pregnancy signifi-
cantly reduced the risk of early neonatal death of their
newborns after adjustment for potential confounders
[10]. Similarly, a pooled analysis from Pakistan on 8512
live births reported maternal antenatal IFA supplements
significantly reduced the adjusted risk of death on day 0
by 33% and during the neonatal period by 29%. Initiating
IFA supplements in the first four months of pregnancy,
significantly reduced the adjusted risk of neonatal
mortality by 35% [11].
IFA supplements have also been found to reduce the
preterm delivery rate and neonatal mortality attributable
to prematurity and birth asphyxia [7]. Other studies
from low-income countries have reported that preterm
delivery is one of the main contributors to neonatal
deaths [12, 13]. These results combined indicate that
IFA supplements in populations of iron-deficient preg-
nant women could lead to a decrease in the number of
neonatal deaths mediated by reduced rates of preterm
delivery. We thus propose a large-scale prospective trial
to measure the impact of the early introduction of ante-
natal iron/folic acid supplementation in pregnancy on
neonatal outcomes in rural Bangladesh. We will employ
a community-based, cluster randomized controlled trial
design, in which pregnant women will be randomly
allocated to the enhanced iron/folic acid distribution
program, or to the current usual programs. We have
chosen the current usual programs as our comparator.
We didn’t consider placebo because WHO and Govern-
ment of Bangladesh have a recommendation that pregnant
women should receive 60 mg of iron supplementation. But
the implementation of this recommendation is inadequate.
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Surveys indicate that only 52% of rural women reported
any use of iron/folic acid in their last pregnancy but this
dropped to 39% for the poorest households, and to 34% for
women with no education (3). Also, the median gestation
when women start antenatal care (and would have access
to iron/folic acid supplements) is 5.2 months (3) .
Objectives and hypothesis
The trial objectives are to evaluate the effect of early
availability and promotion of IFA supplements on neo-
natal mortality, low birthweight and preterm delivery.
The primary hypothesis is that in a community-based,
cluster randomized controlled trial of women from rural
Bangladesh, daily supplementation with 60 mg elemental
iron and 400 μg folic acid starting in the first trimester
of pregnancy, and sustained for at least 180 days, will
reduce neonatal mortality by 25% from 33/1000 to 24.8/
1000 live births compared to usual iron-folic acid
supplementation programs.
The secondary hypotheses are that the early availability
and promotion of IFA supplements in intervention clus-
ters will reduce preterm delivery by 30% (15% in control
to 10.5% in intervention), and low birth weight by 30%
(15% in control to 10.5% in intervention). We further
hypothesised that household wealth and maternal educa-
tion would modify the neonatal mortality responses with
a greater reduction for women from the poorest house-
holds, and women with no education. We also hypothe-
sised that the early start to IFA supplements would not
increase iron-related side effects, e.g. nausea & vomiting
in intervention clusters and will be cost-effective in
reducing neonatal mortality in intervention clusters.
Methods
Study design
This study is a cluster randomised controlled trial, with
2-arm parallel groups, superiority design and 1:1 alloca-
tion ratio. The cohort of the mother-child dyads will be
followed up from recruitment until 42 days after birth.
Study setting
We will conduct the Shonjibon trial in five districts
in Dhaka Division, Bangladesh. These districts are
Netrokona, Kishoreganj, Mymensingh, Sherpur, and
Gazipur, with a total number of 47 Upazila (subdis-
tricts) and a combined population of 20 million. Our
study implementing partner BRAC, a non-government
organisation co-ordinates a community-based mater-
nal, neonatal and child health program in the area
which includes a prospective pregnancy surveillance
and home-based antenatal care program. The Shonji-
bon study area will consist of 24 Upazilas from these
five districts (Fig. 1). We will exclude five Upazilas
from Kishoreganj, six Upazilas from Netrokona and
two Upazilas from Sherpur because of insufficient
BRAC Program Officer (PO) coverage. We will also
exclude three Upazilas from Gazipur because of the
high number of garment industries, which would have
high numbers of working women and would be difficult
to follow-up and eight Upazilas from Mymensingh
because of the high prevalence of malaria and kalazar.
Cluster selection
We will define a cluster as a BRAC PO area, which will
consist of a pair of BRAC village field workers (called
Shasthya Kormi or SK) and their 20 BRAC village volun-
teers (referred to as Shasthya Shebika or SS) who are
supervised by a single BRAC PO. A BRAC PO area
approximately comprises of 40 to 50 villages with an
average population of 13,000 people. We will have a
total number of 112 BRAC PO for randomisation. We
will randomly select 100 clusters with an equal number
of clusters in each arm. The research team took written
approval for the study from Directorate General of
Health Service (DGHS) under Ministry of Health &
Family Welfare before allocating the clusters to a treat-
ment group or the trial interventions begin.
Eligibility criteria for inclusion of cluster
We will exclude any potential BRAC PO area (cluster) if
there are any other maternal and or neonatal interven-
tions either by the government or non-government orga-
nisations in the area. We will identify any such program
by contacting local officials in the sub-districts in the
Dhaka Division. We will exclude areas where access is
extremely difficult, for example in flood-prone areas. All
women aged between 15 to 49 years, who are pregnant
and their gestational age is ≤90 days, and are permanent
residents of the Shonjibon study area will be eligible for
the study.
Formative research
Before the intervention started, we conducted a forma-
tive study using qualitative methods. We collected the
data from July to October 2012, in two villages, one in
Mymensingh and one in Netrokona – two of the five
districts included in the Shonjibon Trial. The field team
consisted of three women and two men trained in
anthropology or social sciences, who had experience in
collecting qualitative data. Four qualitative methods –
in-depth interviews (35 pregnant women, 20 older
women and 11 husbands), key informant interviews (20
with CHWs, program managers, informal care providers,
gynaecologists and traditional birth attendants), focus
group discussions (2 with Shasthya Shebika and 1 with
female college students) and observations of the lowest
level of health facility (community clinics) (2) were con-
ducted. We explore women’s and family members’
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perceptions of: cultural norms during pregnancy; birth
weight; IFA supplementation; and experience using IFA
supplements during pregnancy. We conducted the key
informant interviews to understand the community
norms around IFA supplementation, and challenges and
successes of the existing programme. We used FGDs to
understand both perceptions regarding the need for IFA
tablets during pregnancy and the state of IFA supple-
mentation programmes. In two community clinics, we
conducted an hour-long observation to understand the
implementation of the national IFA programme.
Intervention
From the formative study, we identified culturally appro-
priate and feasible ways of implementing the interven-
tion [14]. The findings of the formative study suggested
that introduction of IFA supplements early in pregnancy
is feasible with support from BRAC or government
community health workers. The formative study also
suggested to include culturally sensitive reasons for the
use of IFA supplements during pregnancy, improvement
of the community health-worker training modules and
to standardise messages across all health workers. We
conducted a pilot study in four BRAC village fieldworker
areas, two with intervention and two comparison areas,
to test the feasibility of our intervention.
Early identification of pregnancy
In the intervention clusters, trained SS will identify preg-
nant women through systematic door-to-door visits of
the households in her catchment area and follow-up
with all women of reproductive age about their recent
history of missed menstrual periods. We will financially
incentivise the SS for early identification of pregnant
women.
Regular supply of IFA supplements and counselling
Upon receiving the consent icddr,b study staff (Field
Implementers or FI) will hand over the first two months
of supply of iron-folic acid capsules, each containing
60 mg of elemental iron and 400μg of folic acid. She will
also counsel the mother about the benefits of IFA sup-
plements in pregnancy. The SS will then make regular
fortnightly visits to the woman until delivery to ensure
resupply of supplements, and provide counselling in
support of early uptake, continued use, and compliance
Fig. 1 Map of study area, Shonjibon Trial (created by the authors)
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with the supplementation regime until delivery. This
intervention is consistent with the Bangladesh Ministry
of Health guidelines.
Improve adherence and monitor compliance
To improve adherence, a local pharmaceutical company
(Eskayef Bangladesh Limited) will produce IFA supple-
ments in an attractive capsule shell and special blister
package. Each strip will consist of 15 capsules. At the
time of enrolment, we will assign each mother a box
consisting of 8 months of supply of iron-folic acid sup-
plements. We will attach the details of the pregnant
women to the box during registration in the trial. At the
time of resupply, the SS will collect the empty strips
from the previous round. If she finds any unused
capsules, she will inquire about the missing doses and
further counsel the women about the importance of
regular consumption of IFA supplements. We will
provide a specially designed medicine box to each
participant to preserve the medicine. It will also serve
as a reminder for regular consumption and safely
store the medicines away from child access. In
addition to this, a special call centre will be set up
centrally where trained nutrition counsellors will sys-
tematically make bi-weekly calls to monitor compli-
ance with the supplementation regime.
Concomitant treatment
The research team will advise all Shonjibon study partic-
ipants in the intervention arm not to consume any add-
itional iron or folic acid supplements from other sources
during her pregnancy.
Management and training
Overall around 3920 SS and 100 FI will deliver the inter-
vention, under the supervision of central field supervis-
ory team. There will be one FI for each cluster. The
central team will comprise of three research fellows, one
medical officer and one research investigator and one
BRAC national manager. The field supervision team will
comprise of five Field Research Officers and five District
Managers. We will train the BRAC village workers and
volunteers in sub-district health centres to detect and
monitor pregnancies, to maintain pregnancy records, to
manage supply and distribution of supplements, com-
munication and counselling skills for behaviour change
related to use of iron-folic acid supplements. The central
team will train the field team and monitor the process of
delivery of the intervention. The BRAC PO will provide
technical support to the SK and SS, and will help
them resolve any problems through regular meetings
in the field.
Control
We used usual iron supplementation program as the
comparator. We will identify and confirm pregnant
women in the control clusters using methods similar to
those described for the intervention arm. Women will
not receive any additional information or counselling
other than usual standard care provided by the existing
BRAC structure. Both intervention and control treat-
ment arms will receive the usual antenatal and postnatal
care services by BRAC.
Trial outcomes
The primary trial outcome will be the difference in the
neonatal mortality rate between the intervention and
control areas. The secondary trial outcomes will include:
(1) percentage of women using IFA supplements in the
first trimester of pregnancy; (2) percentage of live births
with low birth weight and with preterm delivery; (3) per-
centage of neonatal deaths attributable to preterm deliv-
ery, and to birth asphyxia; (4) mean marginal additional
expenditure associated with early IFA supplements, and
the mean cost per neonatal death prevented; (5) the
percentage of pregnant women reporting side effects
including nausea and vomiting.
Outcome measurements
Neonatal deaths
We will investigate all neonatal deaths reported by the SS
to the Field Implementers or by maternal recall at the final
follow-up visit at 42 days postpartum, using standard
questionnaires collected by trained staff. We will use this
data to calculate estimates of neonatal mortality in both
arms from baseline to the end of the intervention period.
Verbal autopsy
Trained Field Research Officers will interview caretakers
of infants who die in the neonatal period using the
World Health Organization (WHO) Standard Verbal
Autopsy Questionnaire [15] within one month of the
death. Investigators will extract and code the symptoms
from both the closed-ended questions and open narra-
tives. We will use physician-certified verbal autopsy
method to identify cases of death related to preterm
delivery and birth asphyxia using the hierarchical assign-
ment of causes of death. At least two physicians will
independently review the data, and they will base their
decision on an agreement. Review by a third physician
will resolve any discrepancy between the two diagnoses.
Birth weight
We will measure birth weight within 24 h of delivery
using standard methods with a portable electronic scale.
The SS will notify the Field Implementers of any births
in their area, and both will visit the mother and her
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infant within 24 h, although measurements will be
accepted up to 72 h after birth.
Duration of gestation
We will measure the duration of gestation will be
measured using the date of last menstrual period with
the pregnancy confirmed by urine test in the field.
Other measurements
Social, economic and demographic characteristics will be
collected in a questionnaire collected at enrolment and
will use standard demographic and health survey methods
of an inventory of household assets to construct a wealth
index, [16] as well as the socio-demographic characteris-
tics of the mother.
Cost-effectiveness analysis
The economic evaluation will take a societal perspective.
We will base the data for the cost-effectiveness analysis
on the costs and outcomes observed in the trial. The costs
of the intervention will include cost and distribution of
the supplements, training of SS workers, organisational
costs associated with the administration of the programme
and the cost of incentives. We will ask the participants to
record use of health services at each follow-up interview,
which will enable assessment of potential cost offsets
particularly associated with differences in rates of birth
complications and neonatal morbidity. We will estimate
incremental cost-effectiveness ratios as incremental cost
per neonate death avoided; per low birth weight infant
avoided and per life-year saved. Years of life saved will be
based on any difference in survival of mothers and infants
observed during the trial and estimated using current life
expectancy in Bangladesh. Standard methods for estimat-
ing uncertainty and a cost-effectiveness acceptability curve
will be generated to provide information on the probabil-
ity that the intervention is cost-effective, at different
willingness to pay thresholds.
Groundwater iron
We will measure the level of groundwater iron in all the
households of our study using a validated test kit tool
[±0.1 mg/L, FerroVer method, HACH Iron Test kit,
Model IR-18B].
Sampling frame and sample size
To detect a 25% reduction in neonatal mortality (33 neo-
natal deaths/1000 live births in control to 24.8 neonatal
deaths/1000 live births in the intervention group), with
90% power, 5% two-sided alpha, 1:1 ratio of treatment allo-
cation and intra-cluster correlation coefficient (ICC) of
0.0245, we require 100 clusters (each covering an average
of 4000 households), or 50 clusters per treatment group,
with a total of 30,000 live births over one year. This sample
would allow detection of a 22% relative difference between
treatment groups with 80% power. To detect a 30% reduc-
tion in preterm delivery from 15% in control compared to
10.5% in the intervention arm, assuming 80% power, 5%
level of significance, intracluster correlation of 0.012 for
small birth size (Bangladesh DHS data), would require a
sample size of 1300/arm or 40 pregnant women from 64
clusters. A smaller sample size of 570 women/arm or 40
pregnant women from 28 clusters is needed to detect a
30% reduction in LBW with the same assumptions. Our
cluster is one BRAC PO area that consists of ~ 13,000
people. Assuming a crude birth rate of 23 per 1000 people,
10% loss of pregnancies before birth and 15% loss to follow
up each cluster will yield 300 births over 15 months, and
this will be sufficient to reach the desired sample size.
Recruitment and consent of women
In the intervention clusters, SSs will make systematic
door-to-door visits to identify new pregnancies through
menstrual cycle tracking of all women of reproductive age.
Once the woman reports a missed period, the SS will im-
mediately notify the Field Implementers by mobile phone.
The Field Implementers will then visit the pregnant mother
along with the SS within the next 48 h to conduct a preg-
nancy test and enquire about the last menstrual period. If
the pregnancy test is positive and the pregnancy is within
the first trimester, the Field Implementers will register the
mother and seek written consent. We will obtain written,
witnessed informed consent from all participants.
Assignment of treatments
An investigator remote from the field area will assign
the interventions to eligible clusters using a fixed
randomisation scheme with a uniform allocation ratio of
treatments, stratified by subdistrict or Upazila. The
random allocation sequence will be generated using Stata
12 software (StataCorp. 2011. Stata Statistical Software: Re-
lease 12. College Station, TX: StataCorp LP). The nature of
the intervention precludes the masking of the treatments.
Evaluation
Data collection team
A separate team of trained data collectors not involved
in the implementation of the intervention will collect
data for evaluation. The evaluation team will consist of
135 data collectors, five field supervisors and five field
research officers. Each data collector will be responsible
for one cluster. We will train the evaluation team over a
four-week period, and standardize measurement methods
and retrain as needed every six months.
Data collection schedule
The data collectors will visit each woman a total number of
six times from the time of enrolment till 42 days after
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delivery. These visits will be made between 12 and
14 weeks, 20–24 weeks, 28–32 weeks, within 24 h of
delivery, 7–10 days after delivery, 38–42 days after
delivery (Fig. 2).
Types of information collected
Over the pregnancy and neonatal period, data collectors will
collect information regarding household characteristics, re-
productive history, pregnancy information, medication his-
tory, details about consumption of IFA supplements, current
health status, any side effects from the supplements, ante-
natal care, birth outcome, birth weight, immediate newborn
care and neonatal deaths. We will also collect information
on exposure to household air pollution and out of pocket ex-
penses for any antenatal and postnatal care seeking (Table 1).
Electronic data collection tool
Data will be captured using an android application de-
veloped using Java. Each data collector will use Samsung
Galaxy 7 in. tablet with Internet enabled SIM card for
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Identify 100 eligible 
BRAC Program Organizers Areas 
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Pregnancy services & 
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Fig. 2 Trial flow chart and intervention schedule
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data collection and transmission of data from the com-
munity to central database server. The application will
navigate the data collectors through a step-by-step
process while interviewing the pregnant women to
collect all required information to be collected at each
specific visit. Some validation rules will be set in the ap-
plication to prevent errors during data collection. Rules
will include logical and range checks, uniqueness check
and skipping rules as appropriate.
Initially, the Field Implementers will enter all the
required registration information of the woman into the
system. As soon as the data is uploaded to the server, in-
formation will be passed to the separate evaluation team
for first follow up visit. Each data collector will need to
log into the system using a pre-assigned unique user ID
and password. During the first visit, the data collector
will download the details of the newly registered preg-
nant women for her assigned cluster from the central
server. This information, filtered according to the
geographical area, comes from the registration data col-
lected by the Field Implementers. During the subsequent
visits, the app will provide each data collector with a list
of women, for whom a follow-up visit is scheduled
within seven days. We will use different colour coding to
highlight visits that are pending or imminent. To verify
physical presence of the data collectors at the
households we will record a Geographic Information
System (GIS) data point. The system will also generate
daily reports of the completed interviews and enrolment
and make them available on the online monitoring inter-
face (in real time). At the end of each interview, the data
collector will store the data on the local device and then
upload the data to the central server after the end of a
day’s work. We will maintain a backup copy of the
database on a different server.
Statistical analysis
Data analysis will be by intention to treat. We will
conduct analyses at the infant level adjusted for the clus-
ter randomisation. The primary analyses will compare
the neonatal mortality rates and their 95% confidence
intervals adjusted for clustering and groundwater iron
level in each group. Secondary analyses will examine
each outcome variable using separate mixed models. We
will use Cox proportional hazards mixed models for
mortality outcomes and include groundwater iron level
as an interaction term in the mortality model. We will
use population average Poisson model for other out-
comes including preterm, small for gestation and low
birth weights. Models will include treatment group as a
fixed effect, community-cluster as a random effect to
account for the cluster effect. The models will evaluate
Table 1 Schedule of enrolment, interventions, and assessments
STUDY PERIOD
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ion Enrolment Post-allocation Close-out
TIME POINTS
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the impact of the interventions over time by testing for
an interaction between time and intervention group. We
will conduct analyses to identify the subgroups (based
on household wealth, sex of infant and maternal educa-
tion) that modify the response to the intervention. We
will check the model assumptions and make appropriate
adjustments to the analysis where necessary. Descriptive
analysis will be performed to present the cause of death.
We will compare the causes of death by sex of newborn,
the time-period of death, and treatment arms (interven-
tion Vs control). χ2 test or Fisher’s Exact test after
adjusting for cluster effect will be used when appropri-
ate. The economic analysis will estimate the incremental
cost per life saved per year of the intervention over
standard care. We will use sensitivity analyses of the
findings to assess uncertainty in key parameters. Stata
V.14 (StataCorp. 2015. Stata Statistical Software: Release
14. College Station, TX: Stata Corp LP.) will be used for
all analyses.
Data monitoring
Electronic data monitoring tool
We will develop an online monitoring system, which will
provide us real-time information on enrolment status,
adherence of the data collectors with the evaluation
schedule and quality of data for key variables. This
system will allow the field supervisors to monitor the
performance of individual data collectors. All reports
will be auto-generated from the system and will be avail-
able anytime for the investigators’ assessment.
Data safety and monitoring board
The research team will establish an independent data
safety and monitoring board (DSMB) consisting of an
independent paediatrician, a clinical trial specialist and a
biostatistician. This DSMB is responsible for assessing
the interim data, data quality, data completeness,
adequacy of compliance with goals for recruitment and
retention, and factors that might affect the study out-
come or compromise the confidentiality of the trial data.
Any unintended effects of trial intervention will also be
notified to data safety and monitoring board.
Advisory committee
To facilitate the overall implementation process and to
engage policymakers and other key decision makers, we
will establish a national project advisory committee con-
sisting of Ministry of Health and Family Welfare staff,
staff, representatives from UNICEF, WHO, the Obstetric
and Gynaecological, the Perinatal, and the Nutrition
Societies of Bangladesh. This committee will assist in
translating the Shonjibon study findings into policy. In
addition, we will establish five district advisory commit-
tees consisting of local health officers, local government
officials, local community groups, other relevant NGOs
and project staff to help guide the research team.
Access to data
All collected data will be accessible by the study investi-
gators. All the investigators will have the right to analyse
and publish data. We will only share datasets with all
personally identifiable information removed, and every
reasonable effort to keep the identification of study
subjects in the strictest confidence.
Dissemination plan
The research team will share the lessons learned from
the study widely throughout Bangladesh and among glo-
bal audiences. The authors will organise dissemination
seminars to share the findings with all relevant stake-
holders. We will present the intermediate and immediate
results, which support the hypotheses generated from
the trial, at national and international conferences and
publish them in conference proceedings. We will publish
the analysis of the outcomes in the form of internal docu-
ments, working papers, and in international peer-reviewed
journals. Authorship eligibility will be based on recom-
mendation from International committee for medical
journals editors (ICMJE).
Discussion
Iron deficiency is associated with increased risk of
maternal death, preterm delivery, impaired foetal growth
and development, low birth weight, increased neonatal
mortality and impaired infant development [17]. In
resource-poor countries, rates of maternal anaemia
remain high. Although the importance of IFA supple-
ments to prevent maternal anaemia and mortality is
widely accepted, most antenatal IFA supplements distri-
bution programs are of low priority. Evaluations of these
programs using maternal anaemia as the outcome report
little or no impact because of the multiple causes of ma-
ternal anaemia, low compliance, and inadequate distri-
bution programs.
Recent surveys in Bangladesh indicate that only 52% of
rural women reported any use of IFA supplements in their
last pregnancy, but this falls to 39% for the poorest house-
holds, and to 34% for women with no education [5]. In
the Projahnmo trial conducted in rural Bangladesh, only
40% of women in the baseline surveys reported any use of
IFA supplements in pregnancy [18]. Access to IFA supple-
ments is through antenatal care, however, in rural
Bangladesh, the median gestation that women commence
antenatal care is 5.2 months, and 44% of women report no
use of antenatal care [5]. The Projahnmo trial demon-
strated improved IFA supplements as 84% of pregnant
women in the home-care treatment arm reported IFA
supplements use in pregnancy [18]. Although they did not
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start early, these figures indicate there is a substantial
opportunity to improve IFA supplements distribution in
rural Bangladesh.
There is limited evidence about the optimal timing of
IFA supplementation in pregnancy. Promising evidence
came from a trial in China investigating the effects of IFA
supplements in pregnancy on neonatal deaths [19]. How-
ever, the neonatal mortality analyses were post-hoc ana-
lyses, and the sample size was small resulting in poor
precision in the effect estimates, and reduced power to ex-
plore all the factors modifying the effects on neonatal mor-
tality. Thus, the impact of early IFA supplements on
neonatal mortality needs confirmation in a larger scale trial.
This project will determine if antenatal IFA supplements
commenced in the first trimester of pregnancy, rather
than later, will significantly reduce neonatal deaths in the
first month of life, and if this approach is cost-effective. It
will also provide valuable evidence about the role of
groundwater iron level in modifying the responses of ante-
natal IFA supplements on neonatal mortality since there is
already some evidence which suggests a positive,
dose-response association between natural iron in ground-
water and the iron status of women [6].
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